Published in J Virol on September 01, 2002
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol (2006) 2.88
Characterization of functional hepatitis C virus envelope glycoproteins. J Virol (2004) 2.40
An in vitro model of hepatitis C virion production. Proc Natl Acad Sci U S A (2005) 1.86
Studying hepatitis C virus: making the best of a bad virus. J Virol (2007) 1.62
Influenza vaccines based on virus-like particles. Virus Res (2009) 1.48
Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol (2004) 1.37
Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol (2004) 1.29
Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J Virol (2003) 1.18
Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J Virol (2005) 1.14
HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. World J Gastroenterol (2006) 1.13
MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol (2013) 1.12
Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology (2009) 1.12
Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol (2007) 0.95
Flow cytometric detection of hepatitis C virus antigens in infected peripheral blood leukocytes: binding and entry. World J Gastroenterol (2005) 0.95
New therapeutic opportunities for hepatitis C based on small RNA. World J Gastroenterol (2007) 0.86
Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front Biosci (Landmark Ed) (2009) 0.86
Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77. J Virol (2014) 0.86
A new model to produce infectious hepatitis C virus without the replication requirement. PLoS Pathog (2011) 0.80
Hepatitis C virus and vaccine development. Int J Mol Cell Med (2014) 0.80
Purification and application of C-terminally truncated hepatitis C virus E1 proteins expressed in Escherichia coli. World J Gastroenterol (2005) 0.79
Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2. Virol J (2011) 0.79
NS2 is dispensable for efficient assembly of hepatitis C virus-like particles in a bipartite trans-encapsidation system. J Gen Virol (2014) 0.77
Monoclonal antibodies against Hepatitis C genotype 3a virus like particle inhibit virus entry in cell culture system. PLoS One (2013) 0.77
Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation. World J Gastroenterol (2005) 0.76
Intracellular targeting with engineered proteins. F1000Res (2016) 0.76
Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies. J Transl Med (2011) 0.76
Assembly and release of infectious hepatitis C virus involving unusual organization of the secretory pathway. World J Hepatol (2016) 0.75
The role of HCV e2 protein glycosylation in functioning of virus envelope proteins in insect and Mammalian cells. Acta Naturae (2015) 0.75
Interactions between Hepatitis C Virus and the Human Apolipoprotein H Acute Phase Protein: A Tool for a Sensitive Detection of the Virus. PLoS One (2015) 0.75
Immortalized Human Hepatic Cell Lines for In Vitro Testing and Research Purposes. Methods Mol Biol (2015) 0.75
Identification of a flavonoid isolated from plum (Prunus domestica) as a potent inhibitor of Hepatitis C virus entry. Sci Rep (2017) 0.75
Hepatitis C virus: The role of N-glycosylation sites of viral genotype 1b proteins for formation of viral particles in insect and mammalian cells. Biochem Biophys Rep (2016) 0.75
Binding of hepatitis C virus to CD81. Science (1998) 12.40
A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med (1992) 8.06
Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science (1997) 7.53
Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat (1999) 6.42
Replication of hepatitis C virus. J Gen Virol (2000) 6.08
Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A (1999) 6.05
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol (1999) 4.99
Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol (1994) 4.21
Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol (1993) 4.13
Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (1992) 3.59
A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J Virol (1998) 3.13
Formation of native hepatitis C virus glycoprotein complexes. J Virol (1997) 2.87
Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol (2000) 2.71
Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol (1998) 2.71
The novel receptors that mediate the entry of herpes simplex viruses and animal alphaherpesviruses into cells. Rev Med Virol (2000) 2.71
Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med (2002) 2.68
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med (2002) 2.64
Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol (1999) 2.52
Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol (2001) 2.50
Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol (2000) 2.50
Hepatitis C virus: detection of intracellular virus particles by electron microscopy. Hepatology (1996) 2.44
Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol (2000) 2.32
Folding, assembly and subcellular localization of hepatitis C virus glycoproteins. Curr Top Microbiol Immunol (2000) 2.15
Characterization of pseudotype VSV possessing HCV envelope proteins. Virology (2001) 2.15
Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. J Viral Hepat (1996) 1.94
Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J Virol (2001) 1.84
Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol (2002) 1.84
The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood (2001) 1.75
Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology (2002) 1.67
Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. J Virol (1998) 1.67
Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science (2000) 1.64
Cell fusion activity of hepatitis C virus envelope proteins. J Virol (2000) 1.50
Mechanisms of enveloped virus entry into animal cells. Adv Drug Deliv Rev (1998) 1.47
Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion. J Virol (2001) 1.45
Role of Ca2+in the replication and pathogenesis of rotavirus and other viral infections. Cell Calcium (2000) 1.30
Buoyant density of hepatitis C virus recovered from infected hosts: two different features in sucrose equilibrium density-gradient centrifugation related to degree of liver inflammation. Hepatology (1994) 1.30
Purified recombinant rotavirus VP7 forms soluble, calcium-dependent trimers. Virology (2000) 1.29
Ultrastructural and physicochemical characterization of the hepatitis C virus recovered from the serum of an agammaglobulinemic patient. Arch Virol (1998) 1.28
Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J Mol Biol (2000) 1.24
Interaction of recombinant norwalk virus particles with the 105-kilodalton cellular binding protein, a candidate receptor molecule for virus attachment. J Virol (2000) 1.15
Characterization of a human follicular thyroid carcinoma cell line (UCLA RO 82 W-1). Virchows Arch B Cell Pathol Incl Mol Pathol (1989) 1.15
A 50-kDa membrane protein mediates sialic acid-independent binding and infection of conjunctival cells by adenovirus type 37. Virology (2001) 1.15
The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood (2001) 1.13
Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells. Virology (2000) 1.11
Hepatitis C virus (HCV) infection and cryoglobulinemia: analysis of whole blood and plasma HCV-RNA concentrations and correlation with liver histology. Hepatology (2000) 1.05
Biochemical requirements of virus wrapping by the endoplasmic reticulum: involvement of ATP and endoplasmic reticulum calcium store during envelopment of African swine fever virus. J Virol (2000) 1.03
Physical interaction of human papillomavirus virus-like particles with immune cells. Int Immunol (2001) 1.02
Hepatitis C virus (HCV) E1 and E2 protein regions that specifically bind to HepG2 cells. J Hepatol (2002) 0.95
Calcium is essential for the structural integrity of the cysteine-rich, ligand-binding repeat of the low-density lipoprotein receptor. Biochemistry (1998) 0.95
Calcium is required in reassembly of bovine papillomavirus in vitro. J Gen Virol (1998) 0.88
Destabilization of herpes simplex virus type 1 virions by local anesthetics, alkaline pH, and calcium depletion. Arch Virol (1989) 0.84
Ultrastructural observations in hepatitis C virus-infected lymphoid cells. Microbes Infect (2001) 0.84
Synthesis of rotavirus-like particles in insect cells: comparative and quantitative analysis. Biotechnol Bioeng (1998) 0.83
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science (2014) 5.47
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology (2007) 3.87
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A (2009) 3.37
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly. Nat Med (2013) 3.24
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology (2004) 2.64
Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med (2010) 2.61
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2009) 2.41
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology (2012) 2.33
Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol (2005) 2.33
Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology (2011) 2.33
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology (2010) 2.28
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology (2012) 2.08
DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.92
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology (2003) 1.91
The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol (2003) 1.90
The SH3 binding motif of HCV [corrected] NS5A protein interacts with Bin1 and is important for apoptosis and infectivity. Gastroenterology (2006) 1.89
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (2003) 1.87
An in vitro model of hepatitis C virion production. Proc Natl Acad Sci U S A (2005) 1.86
Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology (2002) 1.81
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology (2014) 1.74
Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther (2004) 1.72
The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol (2013) 1.72
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology (2007) 1.70
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70
Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology (2002) 1.67
Telegenetics in Maine: Successful clinical and educational service delivery model developed from a 3-year pilot project. Genet Med (2005) 1.67
AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations. Hepatology (2013) 1.64
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (2013) 1.63
Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? J Infect Dis (2013) 1.61
Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis (2010) 1.58
Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Hepatology (2014) 1.52
Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat Med (2012) 1.50
Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology (2004) 1.48
Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology (2006) 1.47
Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology (2006) 1.44
Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology (2010) 1.43
Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol (2009) 1.41
Phenylmethimazole inhibits production of proinflammatory mediators and is protective in an experimental model of endotoxic shock*. Crit Care Med (2012) 1.39
Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol (2004) 1.37
Hepatitis C virus entry: molecular biology and clinical implications. Hepatology (2006) 1.34
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (2003) 1.34
Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology (2011) 1.32
Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology (2010) 1.32
Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol (2004) 1.29
Wnt5a is expressed in murine and human atherosclerotic lesions. Am J Physiol Heart Circ Physiol (2008) 1.28
Production of infectious hepatitis C virus of various genotypes in cell cultures. J Virol (2007) 1.27
Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference. J Pediatr (2006) 1.26
Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A (2003) 1.26
Hepatocyte NAD(P)H oxidases as an endogenous source of reactive oxygen species during hepatitis C virus infection. Hepatology (2010) 1.25
Characterization of determinants important for hepatitis C virus p7 function in morphogenesis by using trans-complementation. J Virol (2009) 1.25
Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis. Clin Infect Dis (2010) 1.25
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A (2007) 1.24
Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A (2007) 1.22
Thyroid hormone action at the cellular, genomic and target gene levels. Mol Cell Endocrinol (2006) 1.19
Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J Virol (2003) 1.18
Hepatitis B e Antigen--the dangerous endgame of hepatitis B. N Engl J Med (2002) 1.18
Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med (2012) 1.18
Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol (2008) 1.17
Inhibition of cellular proteasome activities enhances hepadnavirus replication in an HBX-dependent manner. J Virol (2004) 1.15
Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study. Gastroenterology (2008) 1.15
Effects of mutations of the initiation nucleotides on hepatitis C virus RNA replication in the cell. J Virol (2004) 1.14
Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology (2007) 1.14
Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. Hepatology (2008) 1.14
Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF). Pediatr Radiol (2008) 1.14
Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol (2004) 1.13
Retention of pendrin in the endoplasmic reticulum is a major mechanism for Pendred syndrome. Hum Mol Genet (2002) 1.13
Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology (2009) 1.12